Priority class B candidates (targets without drugs in clinical development but with high-confidence evidence supporting target tractability, such as having high-quality ligand structures for pharmaceutical development [36]) include seven genes, specifically the SL interactors WRN (pan-cancer and COAD/READ), MRPS17 (ESCA), and MTG1 (STAD) and the AL interactors ZNF217 (COAD/READ), RAB7A (ESCA), and ACTR5 (HNSC; priority class B; Fig. 2D–F). This evidence concerns the gene MTG1 and cancer.